Revenue of LEQEMBI (Preliminary Basis)
Filed with TSE · · 1 page · English
Watch Eisai's latest callEisai (Tokyo:4523) Q1 2027 Earnings Call · Replay · Aug 3Read the transcript of Eisai (Tokyo:4523) Q1 2027 Earnings CallEarlier from Eisai
- Historic Step for Alzheimer's Care in Canada: CDA-AMC Recognizes Clinical Value of LEQEMBI® (lecanemab) and Recommends Public Coverage for Early Alzheimer's Disease
- More than 75% of Leqembi®-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world LEADER study data presented at AAIC® 2026
- FDA approves Leqembi Iqlik® (lecanemab-irmb) subcutaneous injection as a starting dose for early Alzheimer's disease
- FDA Approves LEQEMBI IQLIK (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer’s Disease
- UCL and Eisai renew partnership to accelerate treatments for neurodegenerative diseases
Later from Eisai
- Sales of Leqembi® totaled 29.3 billion yen in the second quarter 2026
- CONSOLIDATED FINANCIAL REPORT [IFRS] for the Three-Month Period Ended June 30, 2026
- LEQEMBI (lecanemab) Subcutaneous Formulation as an Initiation Treatment for Early Alzheimer’s Disease Approved in China
- Eisai and Osaka Prefecture Enter into Collaboration to Promote Awareness of Dementia and Mild Cognitive Impairment (MCI)
- LEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) Approved in Japan for the Treatment of Early Alzheimer’s Disease
Follow Eisai into a list and get an email when it puts out news.
Follow Eisai